Victor L. Serebruany
#164,706
Most Influential Person Now
Victor L. Serebruany's AcademicInfluence.com Rankings
Victor L. Serebruanymedical Degrees
Medical
#3373
World Rank
#3841
Historical Rank
Cardiology
#351
World Rank
#362
Historical Rank
Pharmacology
#421
World Rank
#474
Historical Rank
Victor L. Serebruanyphilosophy Degrees
Philosophy
#9636
World Rank
#13225
Historical Rank
Logic
#6606
World Rank
#8139
Historical Rank
Download Badge
Medical Philosophy
Why Is Victor L. Serebruany Influential?
(Suggest an Edit or Addition)Victor L. Serebruany's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium (2011) (3111)
- Variability in platelet responsiveness to clopidogrel among 544 individuals. (2005) (806)
- Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy (2003) (344)
- Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. (2005) (332)
- Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial (2003) (286)
- Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. (2007) (210)
- Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. (2010) (204)
- Risk of bleeding complications with antiplatelet agents: Meta‐analysis of 338,191 patients enrolled in 50 randomized controlled trials (2004) (185)
- Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. (2001) (167)
- Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? (2006) (157)
- Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. (2006) (143)
- Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. (1998) (143)
- Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. (2003) (136)
- Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. (1999) (129)
- Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials (2003) (109)
- NXY-059 for acute ischemic stroke. (2006) (102)
- Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study (2004) (102)
- Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. (2002) (94)
- Neuro-Glial and Systemic Mechanisms of Pathological Responses in Rat Models of Primary Blast Overpressure Compared to “Composite” Blast (2012) (94)
- Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease (2008) (92)
- The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease (2009) (88)
- Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". (2009) (77)
- Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. (2000) (76)
- Assessment of bleeding events in clinical trials--proposal of a new classification. (2007) (76)
- Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. (2005) (76)
- Timing of magnesium therapy affects experimental infarct size. (1995) (75)
- Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer (2004) (75)
- Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified (2011) (73)
- Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. (2004) (73)
- Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin (2003) (72)
- Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. (1999) (71)
- Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. (2001) (71)
- Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. (2000) (70)
- Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). (2006) (70)
- Depression and ischemic heart disease. (2000) (69)
- Effects of Clopidogrel and Aspirin in Combination Versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Patients After Recent Ischemic Stroke: For the Plavix Use for Treatment of Stroke (PLUTO-Stroke) Trial (2005) (67)
- Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study (2007) (67)
- Bleeding risks of combination vs. single antiplatelet therapy: a meta‐analysis of 18 randomized trials comprising 129 314 patients (2008) (63)
- Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. (2010) (59)
- Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. (1998) (57)
- Statins do not affect platelet inhibition with clopidogrel during coronary stenting. (2001) (56)
- Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. (2003) (55)
- Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? (2006) (52)
- Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. (2003) (51)
- Clinical Utility of Available Methods for Determining Platelet Function (2000) (51)
- Soluble VCAM-1 and E-Selectin, but Not ICAM-1 Discriminate Endothelial Injury in Patients with Documented Coronary Artery Disease (2000) (51)
- Impact of clopidogrel and potent P2Y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention (2012) (50)
- Increased soluble platelet / endothelial cellular adhesion molecule‐1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy (1999) (50)
- Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. (2004) (50)
- Time Course of Degradation of Cardiac Troponin I in Patients With Acute ST-Elevation Myocardial Infarction: The ASSENT-2 Troponin Substudy (2006) (48)
- Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size. (1997) (48)
- Clopidogrel: the future choice for preventing platelet activation during coronary stenting? (1999) (47)
- Aspirin inhibits surface glycoprotein IIb/IIIa, P‐selectin, CD63, and CD107a receptor expression on human platelets (2003) (47)
- Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. (2002) (47)
- Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study (2006) (46)
- Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? (2011) (45)
- Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial (2003) (42)
- Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. (2004) (42)
- Enhanced hemostatic indices in patients with pulmonary arterial hypertension: an observational study. (2010) (41)
- Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. (2009) (41)
- Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. (1997) (40)
- Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions (2006) (40)
- Prasugrel as a potential cancer promoter: review of the unpublished data. (2010) (39)
- Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges (2015) (38)
- Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non‐compliance in patient enrolled in the JUMBO Trial (2006) (37)
- Soluble P-selectin Is Not a Surrogate Marker for Platelet P-selectin: Evidence from a Multicenter Chest Pain Study Group (2004) (36)
- Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. (1999) (36)
- Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. (2004) (36)
- Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. (2002) (36)
- Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials – Common patterns in TRITON, RECORD, and PLATO? (2012) (36)
- Evaluation of platelets in heart failure: Is platelet activity related to etiology, functional class, or clinical outcomes? ☆ ☆☆ ★ ★★ (2002) (35)
- Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease (2008) (34)
- Dyspnoea after antiplatelet agents: the AZD6140 controversy (2007) (33)
- Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. (2003) (33)
- A Randomized Trial of Aspirin at Clinically Relevant Doses and Nitric Oxide Formation in Humans (2010) (33)
- Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial) (2002) (33)
- Soluble PECAM-1, but Not P-Selectin, Nor Osteonectin Identify Acute Myocardial Infarction in Patients Presenting with Chest Pain (1999) (33)
- Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. (2003) (33)
- Early Impact of Prescription Omega-3 Fatty Acids on Platelet Biomarkers in Patients with Coronary Artery Disease and Hypertriglyceridemia (2011) (32)
- Increased baseline levels of platelet P‐selectin, and platelet‐endothelial cell adhesion molecule‐1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis (1998) (31)
- Escitalopram, but Not Its Major Metabolites, Exhibits Antiplatelet Activity in Humans (2006) (31)
- Effects of Magnesium Supplementation in a Porcine Model of Myocardial Ischemia and Reperfusion (1994) (31)
- Bolus magnesium infusion in humans is associated with predominantly unfavourable changes in platelet aggregation and certain haemostatic factors. (1997) (30)
- Plasma Triglycerides as Predictors of Platelet Responsiveness to Aspirin in Patients after First Ischemic Stroke (2008) (30)
- Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? (2003) (29)
- Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors (2006) (28)
- Aspirin Increases Nitric Oxide Formation in Chronic Stable Coronary Disease (2013) (28)
- Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel (2011) (28)
- Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). (2003) (28)
- Platelet microRNA for predicting acute myocardial infarction (2017) (27)
- Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. (1998) (26)
- European Stroke Organisation (ESO) (2008) (26)
- The Relations of Major Platelet Receptor Expression during Myocardial Infarction. Monitoring Efficacy of GPIIb/IIIa Inhibitors by Measuring P-selectin? (1999) (26)
- Treatment with selective serotonin reuptake inhibitors for enhancing wound healing. (2004) (26)
- The in vitro effects of niacin on platelet biomarkers in human volunteers (2010) (26)
- Prasugrel development – Claims and achievements (2008) (26)
- Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel (2012) (25)
- Statin Wars: The Heavyweight Match-Atorvastatin versus Rosuvastatin for the Treatment of Atherosclerosis, Heart Failure, and Chronic Kidney Disease (2013) (25)
- Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. (2001) (25)
- Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study (2007) (25)
- The PLATO trial: do you believe in magic? (2010) (25)
- Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy. (2001) (25)
- Incidence and Causes for Early Ticagrelor Discontinuation: A “Real-World” Dutch Registry Experience (2017) (25)
- Depressed Plasma Platelet- Activating Factor Acetylhydrolasein Pat ients Presenting with Acute Myocardial Infarction (1998) (25)
- Effects of Valsartan and Valeryl 4-Hydroxy Valsartan on Human Platelets: A Possible Additional Mechanism for Clinical Benefits (2004) (24)
- The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain: are we comparing apples with oranges. (1999) (24)
- Moderate Alcohol Consumption is Associated with Decreased Platelet Activity in Patients Presenting with Acute Myocardial Infarction (2000) (24)
- Application of platelet function testing to the bedside (2009) (24)
- Noncompliance in cardiovascular clinical trials. (2005) (24)
- Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease (2011) (23)
- Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. (2008) (23)
- Drug Discontinuation and Follow-up Rates in Oral Antithrombotic Trials. (2016) (23)
- Gastrointestinal Adverse Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive (2013) (23)
- The TRITON versus PLATO trials: Differences beyond platelet inhibition (2009) (23)
- Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. (2008) (23)
- Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. (2006) (22)
- Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial (2008) (22)
- Oral Platelet IIb/IIIa Inhibitors: From Attractive Theory to Clinical Failures (2000) (21)
- The "clopidogrel resistance" trap. (2007) (20)
- Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? (2003) (20)
- Viewpoint: “Underutilisation of novel antiplatelet agents – myths, generics, and economics” (2014) (19)
- Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA? (2016) (19)
- Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents. (1998) (19)
- Investigations on 5-HT4 Receptor Expression and Effects of Tegaserod on Human Platelet Aggregation In Vitro (2010) (19)
- Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens? (2009) (19)
- Contribution of platelets indices in the development of contrast-induced nephropathy (2015) (19)
- The Bleeding Risk during Warfarin Therapy Is Associated with the Number of Variant Alleles of CYP2C9 and VKORC1 Genes (2013) (19)
- QT dynamicity, microvolt T-wave alternans, and heart rate variability during 24-hour ambulatory electrocardiogram monitoring in the healthy newborn of first to fourth day of life. (2010) (18)
- Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting. (2016) (18)
- The effect of chronic azithromycin therapy on soluble endothelium-derived adhesion molecules in patients with coronary artery disease. (2000) (18)
- Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm? (2012) (18)
- Exploring the Ticagrelor-Statin Interplay in the PLATO Trial (2013) (18)
- Mortality Benefit in PLATO Cannot Be Explained by Antiplatelet Properties of Ticagrelor (2011) (17)
- Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes (2013) (17)
- Effects of in vitro exposure of alcohol on surface receptor expression of human platelets (2002) (17)
- Recurrent acute stent thrombosis due to allergic reaction secondary to clopidogrel therapy. (2011) (17)
- Endothelial Progenitor Cells and Left Ventricle Function in Patients With Acute Myocardial Infarction: Potential Therapeutic Considertions (2012) (16)
- Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction. (2015) (16)
- Dipyridamole Decreases Protease-Activated Receptor and Annexin-V Binding on Platelets of Poststroke Patients with Aspirin Nonresponsiveness (2006) (16)
- The FDA Prasugrel Review: Adjudication of Myocardial Infarction Controversy (2009) (16)
- Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?). (2008) (16)
- Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids. (2005) (16)
- Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction. (2012) (16)
- Angiotensin Receptor Blockers Worsen Renal Function and Dyspnea on Ticagrelor: A Potential Ticagrelor‐Angiotensin Receptor Blocker Interaction? (2012) (15)
- Dyspnea and Reversibility of Antiplatelet Agents: Ticagrelor, Elinogrel, Cangrelor, and Beyond (2013) (15)
- Statins Increase Risk of Hemorrhagic Stroke by Inhibition of the PAR-1 Receptor (2007) (15)
- Prasugrel in the Poststroke Cohort of the TRITON Trial: The Clear and Present Danger (2008) (15)
- Aspirin Dose and Ticagrelor Benefit in PLATO: Fact or Fiction? (2011) (15)
- Adhesion molecules, platelet activation, and cardiovascular risk. (2002) (14)
- Novel Antiplatelet Agents in Development: Prasugrel, Ticagrelor, and Cangrelor and Beyond (2009) (14)
- Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up (2015) (14)
- Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease. (2000) (14)
- The Dual Antiplatelet Therapy Trial after the FDA Update: Noncardiovascular Deaths, Cancer and Optimal Treatment Duration (2015) (14)
- The Effects of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Platelet and Inflammatory Biomarkers in Patients with Metabolic Syndrome (2013) (14)
- Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice (2017) (14)
- Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke (2010) (14)
- Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation (2009) (14)
- Antiplatelet Activity During Coadministration of the Selective Serotonin Reuptake Inhibitor Paroxetine and Aspirin in Male Smokers: A Randomized, Placebo‐Controlled, Double‐blind Trial (2006) (13)
- Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports (2013) (13)
- Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events. (2015) (13)
- CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans (2017) (13)
- Fluorimetric quantitation of citalopram and escitalopram in plasma: developing an express method to monitor compliance in clinical trials (2007) (13)
- The CYP2C19∗1/∗2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers (2013) (13)
- Myths and realities of P-selectin plasma levels in patients with acute myocardial infarction. (1997) (13)
- The In Vitro Effects of a Novel Vascular Protectant, AGI-1067, on Platelet Aggregation and Major Receptor Expression in Subjects With Multiple Risk Factors for Vascular Disease (2006) (12)
- Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel? (2013) (12)
- Impact of moderate blast exposures on thrombin biomarkers assessed by calibrated automated thrombography in rats. (2013) (12)
- Ticagrelor FDA Approval Issues Revisited (2012) (12)
- Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). (2001) (12)
- Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: challenging PLATO mortality rates. (2013) (12)
- Aggressive antiplatelet strategies: time to reconsider? (2007) (12)
- The In Vitro Effects of Xancor, a Synthetic Astaxanthine Derivative, on Hemostatic Biomarkers in Aspirin-Naïve and Aspirin-Treated Subjects With Multiple Risk Factors for Vascular Disease (2010) (12)
- Dyspnoea after AZD6140: safety first? (2006) (12)
- Excess of Solid Cancers After Prasugrel: The Food and Drug Administration Outlook. (2010) (12)
- Mild COVID-19 and Impaired Blood Cell–Endothelial Crosstalk: Considering Long-Term Use of Antithrombotics? (2021) (12)
- Paradoxical activation of major platelet receptors in the methadone-maintained patients after single pill of aspirin. (2001) (12)
- Whole blood platelet aggregation failed to detect differences between preeclampsia and normal pregnancy (2010) (12)
- Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: The cangrelor efficacy challenge (2013) (12)
- Clopidogrel Response Variability: Impact of Genetic Polymorphism and Platelet Biomarkers for Predicting Adverse Outcomes Poststenting (2015) (12)
- Noninvasive Predictors of Malignant Arrhythmias (2016) (11)
- Noncompliance in antiplatelet trials: the AGATE trial perspective. (2004) (11)
- Validation of Three Platelet Function Tests for Bleeding Risk Stratification During Dual Antiplatelet Therapy Following Coronary Interventions (2016) (11)
- Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction. (1999) (11)
- Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. (2007) (11)
- Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease (2008) (11)
- Hemostatic changes after dietary coenzyme Q10 supplementation in swine. (1996) (11)
- Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. (2000) (11)
- Predicting Bleeding Risk by Platelet Function Testing in Patients Undergoing Heart Surgery (2015) (10)
- Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner? (2015) (10)
- Stability validation of paraformaldehyde-fixed samples for the assessment of the platelet PECAM-1, P-selectin, and PAR-1 thrombin receptor by flow cytometry (2010) (10)
- Assessing Vessel Tone during Coronary Artery Spasm by Dual-Acquisition Multidetector Computed Tomography Angiography (2017) (10)
- Knowledge, attitude and perception of antiplatelet therapy among dentists in Central Eastern Turkey. (2012) (10)
- Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke (2011) (10)
- Viewpoint: Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes (2013) (10)
- Antecedent Aspirin Therapy Inhibits Baseline Platelet Activity in Patients Presenting with Acute Myocardial Infarction (1998) (10)
- Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials. (2013) (10)
- Aptamers: the emerging class of future anticoagulation for vascular disease (2010) (10)
- Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors (2016) (10)
- Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights (2019) (10)
- Usefulness of Combining Necrosis and Platelet Markers in Triaging Patients Presenting with Chest Pain to the Emergency Department (2001) (10)
- Mortality and cancer after 12 versus 30 months dual antiplatelet therapy (2017) (9)
- How magnesium therapy may influence clinical outcome in acute myocardial infarction: review of potential mechanisms. (1996) (9)
- Bleeding Risks with Prasugrel in the TRITON Trial: Good News ... Bad News (2008) (9)
- Platelet Function and Fibrinolytic Agents: Two Sides of a Coin? (2001) (9)
- Effect of Eptifibatide for Acute Coronary Syndromes: Rapid Versus Late Administration—Therapeutic Yield on Platelets (The EARLY Platelet Substudy) (2002) (9)
- Body Mass Index and Plasma P-Selectin before Coronary Stenting Predict High Residual Platelet Reactivity at 6 Months on Dual Antiplatelet Therapy (2018) (9)
- Response to Dual Antiplatelet Therapy Does Not Impact Bleeding Risks in Patients Undergoing Oral Surgery after Acute Coronary Syndromes (2015) (9)
- Worldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug Administration (2018) (9)
- Acute Kidney Infarction Secondary to Intracardiac Thrombus Embolization in a Patient with Ischemic Dilated Cardiomyopathy (2010) (9)
- Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. (2011) (9)
- Optimal aspirin dose in acute coronary syndromes: an emerging consensus. (2014) (8)
- Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting (2008) (8)
- Aspirin in Patients with Coronary Artery Disease: Is it Simply Irresistible? (2001) (8)
- Prasugrel versus clopidogrel. (2008) (8)
- Comment: Mortality Benefit of No-Load Clopidogrel in COMMIT: Not a Surprise (2006) (8)
- Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations. (2010) (8)
- Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy (2016) (8)
- Mortality and adverse events with brand and generic clopidogrel in the Food and Drug Administration Adverse Event Reporting System (FAERS). (2018) (8)
- Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives (2006) (8)
- Unclassified Pleomorphic and Spindle Cell Pulmonary Neoplasm with Brain Metastases after Prasugrel (2013) (8)
- Effect of magnesium sulphate infusion on ex vivo platelet aggregation in swine. (1993) (8)
- Failure of Thrombin Generation Markers to Triage Patients Presenting with Chest Pain (2000) (8)
- Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial? (2007) (8)
- Changes in the haemostatic profile during magnesium deficiency in swine. (1996) (8)
- Aspirin ‘Resistance': Impact on No-Reflow, Platelet and Inflammatory Biomarkers in Diabetics after ST-Segment Elevation Myocardial Infarction (2015) (8)
- P2156 Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin II receptor blockers in patients after acute vascular events (2003) (7)
- Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System (2018) (7)
- Platelet function analyzer (PFA‐100)TM closure time in the evaluation of platelet disorders and platelet function: a rebuttal (2006) (7)
- Clopidogrel and proton pump inhibitors: Gastric protection at expense of vascular benefit? (2009) (7)
- Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting System (2017) (7)
- Antiplatelet ‘resistance’ and ‘non‐responders’: what do these terms really mean? (2009) (7)
- Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: from animal studies to clinical trials. (1998) (7)
- Excessive long-term platelet inhibition with prasugrel or ticagrelor and risk of infection: another hidden danger? (2015) (7)
- Hypoproteinemia in the hemolytic-uremic syndrome of childhood (1993) (7)
- Should We Use Tegaserod for Irritable Bowel Syndrome? (2019) (7)
- Rapid platelet inhibition after a single capsule of Aggrenox®: Challenging a conventional full‐dose aspirin antiplatelet advantage? (2003) (7)
- Mortality in the TRACER and ATLAS ACS 2 Trials: Two More Reasons to Audit Vital Records in PLATO (2012) (7)
- Combination Antiplatelet Therapy with Aspirin and Clopidogrel: The Role of Antecedent and Concomitant Doses of Aspirin (2007) (7)
- Predicting Successful Recanalization in Patients with Native Coronary Chronic Total Occlusion: The Busan CTO Score (2017) (6)
- Vorapaxar: PAR1 receptor antagonist, antiplatelet therapy (2011) (6)
- Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation (2016) (6)
- Hypothesis: Antiplatelet Effects of Selective Serotonin Reuptake Inhibitors Cause Clinical Benefits on Cardiovascular Disease and Increase Risks of Bleeding (2005) (6)
- Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy (2009) (6)
- Redesigning TRACER trial after TRITON. (2015) (6)
- Enhanced platelet reactivity in pediatric depression: an observational study (2013) (6)
- Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor? (1997) (6)
- Controlled Rosuvastatin Multinational Trial In Heart Failure (the positive negative trial). (2008) (6)
- Reteplase but not Alteplase Affects Early Soluble PECAM-1 and P-selectin Release in Patients with Acute Myocardial Infarction (1998) (6)
- Regional and systemic platelet function is altered by myocardial ischemia-reperfusion (2005) (6)
- The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting. (2016) (6)
- Hypokalemia, Cardiac Failure, and Reporting NXY-059 Safety for Acute Stroke (2006) (6)
- Refuting the ticagrelor-aspirin black box warning: and proposing a ticagrelor early-PCI black box warning. (2013) (6)
- Pretreatment with an inhibitor of mac-1 alters regional and systemic platelet function during ischemia-reperfusion in swine. (1996) (6)
- Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty. (2013) (6)
- Platelets and Thrombolysis: Cooperation or Contrariety? (2001) (6)
- Assessment of platelet activity by measuring platelet-derived substances in plasma from patients with acute myocardial infarction: surprising lessons from the GUSTO-III Platelet Study. (1999) (6)
- Survival After Solid Cancers in Antithrombotic Trials. (2015) (5)
- Mild Myocardial Stunning Affects Platelet Aggregation and Certain Hemostatic Factors in Swine (1999) (5)
- Fatal sepsis and systemic inflammatory response syndrome after off-label prasugrel: a case report. (2014) (5)
- Platelet activation as a universal trigger in the pathogenesis of acute coronary events after cocaine abuse. (2001) (5)
- Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths. (2017) (5)
- Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association? (2017) (5)
- Failure of Platelet Parameters and Biomarkers to Correlate Platelet Function to Severity and Etiology of Heart Failure in Patients Enrolled in the EPCOT Trial (2002) (5)
- Verifying Death Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2020) (5)
- Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy. (2016) (5)
- Thrombin Generation and Platelet Reactivity at Hospital Discharge and 6-Month Outcome after the Acute Coronary Syndrome in Diabetic and Nondiabetic Patients (2014) (5)
- Plasma fibronectin during myocardial ischemia‐reperfusion: Effects of magnesium, diltiazem, and a novel Mac‐1 inhibitor (1998) (5)
- Abstract 3803: Platelet Inhibition with Prasugrel (CS-747) versus Clopidogrel in Patients Undergoing Coronary Stenting: The Subset From the JUMBO Trial (2006) (5)
- Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers (2007) (5)
- Effect of Coronary Thrombolysis on the Plasma Concentration of Osteonectin (SPARC, BM40) in Patients with Acute Myocardial Infarction (2000) (5)
- All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. (2019) (5)
- Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens? (2000) (5)
- Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction. (1994) (5)
- Optimization of Anticoagulation with Warfarin for Stroke Prevention: Pharmacogenetic Considerations (2011) (5)
- Monitoring Platelet Inhibition during Chronic Oral Platele Glycoprotein IIb/IIIa Blockade: Are We Missing Somethintg? (2000) (5)
- Aggrenox® (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events (2002) (5)
- Significant excess of early deaths after prehospital ticagrelor: The ATLANTIC trial challenge (2015) (4)
- Storing paraformaldehyde-fixed whole blood patient samples after chronic platelet glycoprotein IIb/IIIa blockade: core laboratory considerations. (1999) (4)
- Dose of aspirin and bleeding risks. (2006) (4)
- Hemostatic changes after early versus late intracoronary magnesium during acute myocardial infarction in swine. (1996) (4)
- Decreased intraplatelet Ca2+ release and ATP secretion in pediatric nephrotic syndrome (1999) (4)
- Combining Necrosis and Platelet Markers for Perfecting Myocardial Infarction Rule Out: How Close Are We? (2000) (4)
- Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. (2012) (4)
- Troponin I and D-Dimer for Discriminating Acute Pulmonary Thromboembolism from Myocardial Infarction (2016) (4)
- Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? (2007) (4)
- Exploring PLATO-USA paradox and CURRENT-OASIS 7 trials reveals the benefit of higher aspirin dose. (2015) (4)
- The Antiarrhythmic Properties of Quifenadine, H1-Histamine Receptor Blocker in Children with Premature Beats: A Randomized Controlled Pilot Trial (2009) (4)
- Amount of paraformaldehyde for sample fixation markedly affects the quality of platelet assessment by flow cytometry: experience from two clinical trials. (2000) (4)
- Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor (2018) (4)
- NPC 15669, an antiinflammatory leucine derivative, reduces in vitro platelet aggregability in both swine and human plasma (2005) (4)
- AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis (2007) (4)
- Thienopyridine reloading in clopidogrel-loaded patients undergoing percutaneous coronary interventions: The PRAISE study. (2016) (4)
- Prasugrel, clopidogrel, and combining Swedish apples with American oranges. (2006) (4)
- Prasugrel: the real-life perspective. (2013) (4)
- Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. (1997) (4)
- Mortality in the TRITON trial: update from the FDA prasugrel action package. (2010) (4)
- Switching from Generic to Brand Clopidogrel in Male Patients after ST-Elevated Myocardial Infarction (2014) (4)
- Serial changes of soluble endothelin-1 levels during myocardial ischaemia-reperfusion. Effects of magnesium, diltiazem and a novel MAC-1 inhibitor. (1998) (3)
- Vorapaxar for secondary stroke prevention: perspectives and obstacles (2015) (3)
- Predicting bleeding risk by simplified PRECISE-DAPT score. (2020) (3)
- Missed bleeding events after ticagrelor in PEGASUS trial: Massive non-compliance, information censoring, or both? (2016) (3)
- A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study (2017) (3)
- Realistic assessment of drug-induced adverse events: a double-edged sword. (2010) (3)
- Challenging Anticoagulation in Advanced Renal Failure. (2019) (3)
- Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- (2010) (3)
- The FDA and PLATO Investigators death lists: Call for a match (2021) (3)
- Long-term clinical outcomes after successful and failed recanalization to native chronic Total occlusion: Insights from the Busan chronic Total occlusion (B-CTO) Registry. (2016) (3)
- The challenge of monitoring platelet response after clopidogrel. (2008) (3)
- Are drug regulators really too slow? (2017) (3)
- CRUSADE Score is Superior to Platelet Function Testing for Prediction of Bleeding in Patients Following Coronary Interventions☆ (2017) (3)
- Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade? (2021) (3)
- Asymptomatic Pulmonary Embolism after Ablation (2016) (3)
- Low platelet activity predicts 30 days mortality in patients undergoing heart surgery (2016) (3)
- The FDA report on vorapaxar in the elderly: A convoluted dilemma. (2015) (3)
- Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19. (2021) (3)
- Future of oral antiplatelet therapy: Four challenged hypotheses (2009) (3)
- Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting (2017) (3)
- Lack of outcome benefit and clopidogrel “resistance” (2009) (3)
- Extreme All-Cause Mortality in JUPITER Requires Reexamination of Vital Records (2011) (3)
- Impact of marital status on outcomes following ST-segment elevation myocardial infarction. (2017) (3)
- [The differences between the guidelines of the European Society of Cardiology and the American College of Cardiology/ American Heart Association for oral P2Y12 inhibitor therapy in the management of patients with acute coronary syndromes]. (2013) (3)
- Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. (2002) (3)
- Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS) (2017) (3)
- Discrepancies in the primary PLATO trial publication and the FDA reviews. (2014) (3)
- Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine. (1996) (3)
- Relation of coronary collateral circulation with epicardial fat volume in patients with stable coronary artery disease (2013) (2)
- Selective Serotonin Reuptake Inhibitors: Future Treatment of Vascular Disease? (2001) (2)
- Prasugrel for arterial coronary thrombosis. (2009) (2)
- Crossreactivity of Human versus Swine Platelet Surface Antigens Is Similar for Glycoproteins Ib and IIIa, but Not for the Glycoprotein IIb/IIIa Complex (2004) (2)
- Misreported Cancer Deaths in PLATO Trial (2021) (2)
- Impact of CYP2C19 Polymorphism on Antiplatelet Potency of Prasugrel 5 and 10 mg Daily Maintenance (2018) (2)
- Dyspnoea after AZD 6140: blaming the messenger (2007) (2)
- Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. (1996) (2)
- Chapter 4 Myocardial cell injury during ischemia and reflow (1998) (2)
- Antiplatelet therapy: Aspirin in the elderly — tailored approaches ahead? (2017) (2)
- De-Escalation of Dual Antiplatelet Regimens in East Asian Patients Undergoing Coronary Intervention. (2020) (2)
- Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial (2016) (2)
- Activated Hemostatic Biomarkers in Patients with Implanted Left Ventricle Assist Devices: Are Heparin and/or Clopidogrel Justified? (2015) (2)
- The action of dipyridamole to prevent thrombosis: Practical implications for the treatment and prevention of stroke (2006) (2)
- Statins in general and atorvastatin in particular do not affect platelet inhibition with clopidogrel during coronary stenting (2003) (2)
- Comparison of ACUITY, CRUSADE, and GRACE Risk Scales for Predicting Clinical Outcomes in Patients Treated with Dual-Antiplatelet Therapy (2018) (2)
- Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives (2007) (2)
- Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction. (1999) (2)
- Effect of Tenecteplase versus Alteplase on Platelets in Patients during the First Three Hours after Acute Myocardial Infarction (the ASSENT-2 Platelet Substudy) (2001) (2)
- Delays of Event Adjudication in the TRITON Trial (2010) (2)
- Clopidogrel and heart failure survival: missed opportunity or wrong turn? (2010) (2)
- Spectrofluorimetric assessment of plasma dipyridamole stability: sample storage for multicenter clinical trials? (2008) (2)
- Late prasugrel benefit in STEMI patients? (2009) (2)
- Cost–effectiveness of antiplatelet therapy for secondary stroke prevention (2007) (2)
- Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers. (2019) (2)
- Effects of zoloft® on platelet/endothelial biomarkers in depressed patients after acute coronary events: Sertraline Anti-Depressant Heart Attack Randomized Trial (SADHART platelet substudy) (2002) (2)
- The FDA Outlook of Events Reporting after Ticagrelor or Clopidogrel in the PLATO Trial: Impact of Sponsor Censoring Dates, Drug Discontinuation, and Withdrawal of Consent (2012) (2)
- Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients? (2020) (2)
- Take an Aspirin or Have a Drink: Antecedent Aspirin and Moderate Alcohol Consumption Similarly Affect Baseline Platelet Characteristics in Patients with Acute Myocardial Infarction (2000) (1)
- Angiographic Outcomes Contradict Platelet Data in the PLATO Trial: Confusion over Official Trial Substudies (2014) (1)
- Erratum to: Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice (2017) (1)
- Abstract 851: Usual Doses of Aspirin Markedly Increase Nitric Oxide Formation in Humans (2009) (1)
- Clinical Study The CYP 2 C 19 ∗ 1 / ∗ 2 Genotype Does Not Adequately Predict Clopidogrel Response in HealthyMalaysian Volunteers (2015) (1)
- 2230Adverse event profiles after brand or generic clopidogrel in the Food and Drug Administration Adverse Event Reporting System (FAERS) (2018) (1)
- The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect. (2016) (1)
- Impact of Valve Surgery on Serum Osteopontin Levels in Patients with Mitral Regurgitation (2015) (1)
- Survival in Acute Myocardial Infarction Induced by Coronary Ligation: Prognostic Relevanceof Certain Hemostatic Factors During the Occlusion Phase (2004) (1)
- Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes (2013) (1)
- The moving target of clopidogrel response variability: new tricks of the old dog? (2016) (1)
- Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial. (2016) (1)
- Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation (2012) (1)
- Von Willebrand factor for predicting bleeding and mortality real deal or another failed biomarker? (2011) (1)
- Potential benefits of prasugrel and ticagrelor is diabetics are not substantiated by the Food and Drug Administration adverse event repository. (2018) (1)
- Abstract 5881: The in vitro Effects of E5555, a PAR-1 Antagonist, on Platelet Biomarkers in Healthy Volunteers and Patients With Coronary Artery Disease (2009) (1)
- Changes of Ticagrelor Formulary Tiers in the USA: Targeting Private Insurance Providers away from Government-Funded Plans (2013) (1)
- Effects of a novel leumedin NPC 15669 on myocardial stunning and preconditioned infarction size in swine (2005) (1)
- Infections Deaths in the PLATO Trial (2021) (1)
- Meta-analyses of incomplete trial datasets: unreliable and potentially misleading (2017) (1)
- Telmisartan and Stroke Reduction in the ONTARGET Trial: Benefit beyond Blood Pressure Lowering? (2008) (1)
- Less Myocardial Infarction and Stroke Hospitalizations During Middle East Respiratory Syndrome Coronavirus Epidemic in Korea (2020) (1)
- Effect of Sulodexide on Circulating Blood Cells in Patients with Mild COVID-19 (2022) (1)
- Tuesday, 28 August 2012 (2012) (1)
- Profound inhibition of GPIb, GPIIb/IIIa, PECAM-1, CD63, and CD107 in a chronic drug addict: selecting controls for platelet flow cytometry in the inner city hospital. (2001) (1)
- Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar (2015) (1)
- Valves in the Heart of the Big Apple VI: Evaluation and Management of Valvular Heart Diseases 2010 (2010) (1)
- Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: A possible missing link to explain reduction of acute vascular events with angiotensin II receptor blockers (2003) (1)
- Plasma clopidogrel metabolites and antiplatelet "resistance": back to the future. (2008) (1)
- Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible (2018) (1)
- Switching thienopyridines: hypothetical versus real risks. (2008) (1)
- Vorapaxar and optimal aspirin dose: The FDA outlook. (2016) (1)
- Late Silent Stent Abscess (2015) (1)
- Effects of FX06 In Vitro on Platelet, Coagulation, and Fibrinolytic Biomarkers in Volunteers and Patients With Documented Coronary Artery Disease (2014) (1)
- P610Assessing cancer signal during oral antiplatelet therapy in the food and drug administration adverse event reporting system (2018) (0)
- Mac-1 inhibitor affects certain hemostatic parameters during myocardial stunning in swine. (1996) (0)
- Superior early periprocedural efficacy of prasugrel over ticagrelor in patients after stenting. (2017) (0)
- Effects of Mac-1 inhibitor on hemostasis during myocardial stunning in swine (1996) (0)
- GW27-e0575 Impact of Renal Impairment on Platelet Reactivity and Clinical Outcomes During Chronic Dual Antiplatelet Therapy Following Coronary Stenting (2016) (0)
- We-P11:212 Platelet inhibition with prasugrel (CS-747) versus clopidogrel in patients undergoing coronary stenting (Jumbo platelet substudy) (2006) (0)
- P3464 The risk of bleeding complications with antiplatelet agents: a meta-analysis of 338, 191 patients enrolled in 50 randomized controlled trials (2003) (0)
- Reply (2011) (0)
- Contents Vol. 138, 2017 (2017) (0)
- P3508Validation of acute pulmonary thromboembolism discrimination from myocardial infarction by using Troponin I and D-dimer (2017) (0)
- GW27-e0524 Predictors of Successful Recanalization in Patients with Native Coronary Chronic Total Occlusion: The B-CTO (Busan Single-center CTO Registry) Score (2016) (0)
- Plasma levels and platelet expression of P-selectin in patients with acute myocardial infarction after thrombolytic therapy: indicator of successful reperfusion? (1998) (0)
- Adjunctive Cilostazol in Patients With High Residual Platelet Reactivity After Drug-Eluting Stent Implantation: A Randomized, Open-Label, Single-Center, Prospective (ADJUST-HPR) Study. (2023) (0)
- Apparent Non-Cited Overlap between Two Published Articles by the Same Group of Authors (2010) (0)
- Use of valsartan metabolism to inhibit platelet aggregation. (2003) (0)
- Contents Vol. 111, 2008 (2008) (0)
- Erratum to: “Comparison of ACUITY, CRUSADE, and GRACE Risk Scales for Predicting Clinical Outcomes in Patients Treated with Dual-Antiplatelet Therapy” (2019) (0)
- We-P11:211 AGI-1067, an antioxidant, anti-inflammatory vascular protectant, reduces activity of human platelets (2006) (0)
- Contents Vol. 120, 2011 (2012) (0)
- Impact of VKORC1, CYP2C9, and CYP4F2 Polymorphisms on Optimal Warfarin Dose: Does Ethnicity Matters? (2021) (0)
- Introduction. Antiplatelet therapy in ACS and A-Fib. (2012) (0)
- Late Common Iliac Artery Stent Thrombosis in a Patient with Terminal Malignancy (2010) (0)
- Subject Index Vol. 117, 2010 (2011) (0)
- Predicting clinical outcomes after clopidogrel use: easier to postulate than to prove and implement. (2019) (0)
- Effects of intracoronary diltiazem on certain hemostatic parameters during acute myocardial infarction in swine. (1997) (0)
- Ticagrelor and heart surgery controversy: we may have better antiplatelet options. (2016) (0)
- Effect of Aliskiren and Valsartan Combination Versus Aliskiren Monotherapy on Hemostatic Biomarkers in Hypertensive Diabetics: Aliskiren and Valsartan Impact in Diabetics Pilot Trial (2014) (0)
- Impact of Bleeding on Myocardial Infarction, Stroke and Death During 12-months Dual Antiplatelet Therapy After Acute Coronary Syndrome. (2022) (0)
- Subject Index Vol. 92, 1999 (2000) (0)
- P1746Comparison of influencing factors on platelet reactivity in various platelet function test after percutaneous coronary interventions (2017) (0)
- P500Stroke and mortality rate after percutaneous coronary intervention vs coronary artery bypass grafting using Korean National Health Insurance Service (NHIS) sample cohort database (2017) (0)
- Subject Index Vol. 111, 2008 (2008) (0)
- Subject Index Vol. 107, 2007 (2006) (0)
- Welcome Address – from the Editors (2000) (0)
- Mortality after clopidogrel in the non-invasive PLATO cohort and TRILOGY ACS trial: another mismatched death paradox. (2013) (0)
- The Algorithm with Multiple Genotypes on Optimal Warfarin Doses in Korean Patients (2020) (0)
- Newer Antiplatelet Agents for Interventional Indications (2014) (0)
- ASSOCIATION OF PLATELET RESPONSIVENESS WITH CLOPIDOGREL METABOLISM: ROLE OF COMPLIANCE IN THE ASSESSMENT OF “RESISTANCE” (2010) (0)
- Subject Index Vol. 115, 2010 (2010) (0)
- Monographs: Prasugrel for arterial coronary thrombosis (2009) (0)
- Subject Index Vol. 1, 2001 (2001) (0)
- Valves in the Heart of the Big Apple V: Evaluation and Management of Valvular Heart Diseases 2007.Third Annual Scientific Session: Heart Valve Society of America, New York City, N.Y., April 12–14, 2007 (2007) (0)
- Abstract 2396: Consistent Platelet Inhibition After Chronic Maintenance Dose Clopidogrel Therapy Among 359 Compliant Outpatients with Documented Ischemic Stroke and Coronary Artery Disease (2006) (0)
- 931-110 Effects of NPC 15669 on Myocardial Stunning and Infarction Size (1995) (0)
- Enoxaparin dose impacts blood cell phenotypes during mild SARS-CoV-2 infection: the observational single-center study. (2021) (0)
- Ivabradine for heart failure: regulatory differences in Europe and United States. (2019) (0)
- 1141-197 Detection of aspirin resistance in subjects with multiple risk factors for cardiovascular disease (2004) (0)
- Oral Anticoagulants and Renal Impairment: The Convoluting Dilemma (2016) (0)
- Antiplatelet therapy in ACS and A-Fib (2012) (0)
- 5942Stroke rate after long-term antiplatelet medication strategy in percutaneous coronary intervention patients using Korean National Health Insurance Service (NHIS) customized health information database (2017) (0)
- Abstract 3889: Antecedent Aspirin Dose and Platelet Inhibition with Clopidogrel in Patients After Coronary Stenting and Ischemic Stroke: Analysis of 711 cases of Dual Antiplatelet Therapy (2006) (0)
- Contents Vol. 115, 2010 (2010) (0)
- Letter by Serebruany and DiNicolantonio regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". (2013) (0)
- International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic? (2015) (0)
- Front & Back Matter (2013) (0)
- Contents Vol. 136, 2017 (2017) (0)
- The Reply. (2017) (0)
- P4440Mortality after novel oral anticoagulants versus warfarin in the food and drug administration adverse event reporting system (2017) (0)
- Abstract 3478: Risk of Bleeding Associated with Combination versus Single Antiplatelet Agents in 142,916 Patients Enrolled in 22 Randomized Controlled Trials (2007) (0)
- Consistent Platelet Inhibition During Long-Term Maintenance Clopidogrel Therapy Among Three Hundred Fifty-Nine Compliant Outpatients with Documented Vascular Disease (2007) (0)
- Evidence-Based therapy and C-reactive protein levels in outpatients with mild to moderate heart failure (2003) (0)
- Effect of a single dose of aspirin (325 mg) on platelets in human volunteers with multiple risk factors for coronary artery disease (2002) (0)
- 1254 Optimising cardiovascular pharmacotherapy / Vascular smooth muscle in development and genetic disease (0)
- Contents Vol. 1, 2001 (2001) (0)
- Mortality after clopidogrel in the non-invasive PLATO cohort and TRILOGY ACS trial (2013) (0)
- Is age related to platelet activity in patients presenting with acute coronary syndromes (2002) (0)
- Heparin Prevents Xylum Clot Signature Analyser to Detect Platelet Inhibition with Clopidogrel During Coronary Stenting (2001) (0)
- Contents Vol. 134, 2016 (2016) (0)
- Time course of death after acute coronary syndrome treated with dual antiplatelet therapy for one year. (2023) (0)
- Dose of aspirin and bleeding risks. Commentary (2006) (0)
- How rapidly and durably are platelets inhibited by a 300 mg clopidogrel loading dose given at the time of intervention compared to loading before intervention (2002) (0)
- Contents Vol. 107, 2007 (2006) (0)
- The Perils of Data Sharing, Meta-analyses, and Estimating Rosiglitazone Cardiovascular Risk. (2020) (0)
- P4438Mortality after oral platelet p2y12 inhibitors in the food and drug administration adverse event reporting system (2017) (0)
- Editors’ Introductory Note (2002) (0)
- The Reply. (2017) (0)
- P6108ACUITY risk score better predicts 30-days major cardiovascular events than CRUSADE and GRACE risk scores in acute coronary syndrome (2017) (0)
- Editors’ Introductory Note (2001) (0)
- Effects of Extended-Release Dipyridamole In Vitro on Thrombin Indices Measured by Calibrated Automated Thrombography in Poststroke Survivors (2012) (0)
- P4008Stroke rate after twelve versus 30 month dual antiplatelet therapy in percutaneous coronary intervention patients using Korean National Health Insurance Service (NHIS) (2017) (0)
- Subject Index Vol. 4, 2004 (2004) (0)
- Acute coronary syndromes, response to clopidogrel, and worsened cardiovascular outcomes: the hen and the egg dilemma. (2006) (0)
- Primary Causes of Death Reported to the FDA Suggest Less Ticagrelor Mortality Benefit than the List Issued to the PLATO Trial Investigators (2022) (0)
- Reply (2012) (0)
- FDA PLATO deaths list challenges aspirin dose-ticagrelor interaction. (2021) (0)
- P1814Deaths and vascular outcomes with non-vitamin K oral anticoagulants versus warfarin in patients with heart failure in the food and drug administration adverse event reporting system (2018) (0)
- Retaplase plus abciximab improves non-fatal outcomes, but not overall survival in people with diabetes and acute ST-segment elevation myocardial infarction (2004) (0)
- Comment and Reply on: The dose of aspirin for the prevention of cardiovascular and cerebrovascular events (2006) (0)
- Mild myocardial stunning affects platelet aggregation and hemostasis in swine (1996) (0)
- Current concepts targeting antiplatelet 'resistance'. (2008) (0)
- Platelet function and total length of intracoronary stents: is there a correlation? (2001) (0)
- Dyspnoea after AZD6140 : safety first? Author's reply (2006) (0)
- Contents Vol. 4, 2004 (2004) (0)
- P2482Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System (FAERS) (2017) (0)
- Biomarkers and Exercise Training: A Possible Missing Link between Physical Activity and Mortality Benefit in Patients with Heart Failure (2001) (0)
- Some Thoughts from Your Publisher (2001) (0)
- Contents Vol. 117, 2010 (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Victor L. Serebruany?
Victor L. Serebruany is affiliated with the following schools:
